Ensysce Biosciences (ENSC) Net Income towards Common Stockholders Growth (3y) (2021 - 2025)
Ensysce Biosciences (ENSC) Net Income towards Common Stockholders Growth (3y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 62.15% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 27.77% |
| Jun 30, 2025 | 39.94% |
| Mar 31, 2025 | -5.29% |
| Dec 31, 2024 | 30.98% |
| Sep 30, 2024 | 26.80% |
| Jun 30, 2024 | -28.13% |
| Mar 31, 2024 | -50.86% |
| Dec 31, 2023 | -163.88% |
| Sep 30, 2023 | -54.84% |
| Jun 30, 2023 | -229.27% |
| Mar 31, 2023 | -47.74% |
| Dec 31, 2022 | -26.13% |
| Sep 30, 2022 | -181.10% |
| Jun 30, 2022 | -176.31% |
| Mar 31, 2022 | -60.67% |
| Dec 31, 2021 | -156.89% |
| Sep 30, 2021 | -216.53% |
| Jun 30, 2021 | -62.03% |
| Mar 31, 2021 | -61.80% |